Compound News and Research

RSS

USPTO grants patent for galactomannan-based carbohydrate galectin inhibitor compounds

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for a divisional patent of Patent Number 8,236,780 "Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies".

26 Nov 2012

Researchers characterize novel lysosomal PQ protein linked to cystinosis

Researchers at the Université Paris Descartes/CNRS and the Université libre de Bruxelles have made a major breakthrough in the study of cystinosis, a genetic disease that can lead to serious disorders, notably fatal kidney failure.

23 Nov 2012

Iridoid synthase can make powerful chemicals from catnip to vinblastine

Scientists have discovered an enzyme used in nature to make powerful chemicals from catnip to a cancer drug, vinblastine. The discovery opens up the prospect of producing these chemicals cheaply and efficiently.

22 Nov 2012

Citicoline not superior to placebo in treating traumatic brain injury

Although approved for use for treating traumatic brain injury (TBI) in nearly 60 countries, use of citicoline in a randomized trial that included more than 1,200 participants with TBI did not result in improvement in functional and cognitive status, according to a study appearing in the November 21 issue of JAMA.

22 Nov 2012

Study: 2-PMPA improves cognition in mice with MS

Johns Hopkins researchers report the successful use of a form of MRI to identify what appears to be a key biochemical marker for cognitive impairment in the brains of people with multiple sclerosis (MS). In follow-up experiments on mice with a rodent form of MS, researchers were able to use an experimental compound to manipulate that same marker and dramatically improve learning and memory.

21 Nov 2012

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).

19 Nov 2012

CLR01 effectively inhibits synaptotoxicity in mice with Alzheimer's

Last March, researchers at UCLA reported the development of a molecular compound called CLR01 that prevented toxic proteins associated with Parkinson's disease from binding together and killing the brain's neurons.

16 Nov 2012

D737 compound restores motor function and longevity in fruit flies with Alzheimer's

An efficient, high-volume technique for testing potential drug treatments for Alzheimer's disease uncovered an organic compound that restored motor function and longevity to fruit flies with the disease, according to new research that could help put the search for an effective Alzheimer's drug on a faster track.

16 Nov 2012

RXi announces pharmacokinetic results from RXI-109 Phase 1 study in healthy subjects

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.

15 Nov 2012

Viewpoints: Voters want Medicare protected in 'grand bargain;' Increases in taxes can't cover the 'fiscal cliff'; Kids' health needs more attention

As the ranking member on the House Financial Services Subcommittee on Domestic Monetary Policy and Technology, let me simply state the hard truth. To avoid the fiscal cliff and to get our budget deficit and the national debt under control, we need to do three things simultaneously: cut spending, increase revenue and have the courage to put everything on the table in a responsible, bipartisan manner.

15 Nov 2012

Brevetoxin-2 stimulates nerve cell growth and plasticity in cultured mouse neurons

A new study using brevetoxin-2, a compound produced naturally by marine algae, stimulated nerve cell growth and plasticity in cultured mouse neurons. This research advances a potentially new pharmacological treatment to aid recovery of brain function following a stroke or other traumatic brain injury.

14 Nov 2012

Combination of hormones may effectively treat obesity with few side effects

Scientists at Indiana University and international collaborators have found a way to link two hormones into a single molecule, producing a more effective therapy with fewer side effects for potential use as treatment for obesity and related medical conditions.

14 Nov 2012

Taste receptor governs respiratory infection susceptibility

The bitter taste receptor TAS2R38 may play a role in innate defense, say researchers, who have found that variations in the TAS2R38 gene may regulate susceptibility to respiratory infection.

12 Nov 2012

HCT 1026 may help stem debilitating effects of muscular dystrophy

Cedars-Sinai Heart Institute researchers have found that an experimental compound may help stem the debilitating effects of muscular dystrophy by restoring normal blood flow to muscles affected by the genetic disorder.

9 Nov 2012

UIC researchers develop transgenic Alzheimer's mouse with apoE4 gene

Researchers at the University of Illinois at Chicago College of Medicine have developed a transgenic mouse that carries a human gene known to increase risk of Alzheimer's 15-fold. This new mouse mimics the genetics of the human disease more closely than any of the dozen existing mouse models and may prove more useful in the development of candidate drugs to prevent or treat the disease.

9 Nov 2012

Study reveals increased risk of leukemia among Chernobyl cleanup workers

A 20-year study following 110,645 workers who helped clean up after the 1986 Chernobyl nuclear power plant accident in the former Soviet territory of Ukraine shows that the workers share a significant increased risk of developing leukemia. The results may help scientists better define cancer risk associated with low doses of radiation from medical diagnostic radiation procedures such as computed tomography scans and other sources.

8 Nov 2012

Washington University, SRI investigators launch Global Metabolomic Initiative

Investigators at Washington University and The Scripps Research Institute have announced the launch of a "Global Metabolomic Initiative" to facilitate meta-analyses on studies of the metabolism of bacteria, yeast, plants, animals and people.

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Scientists identify group of small molecules that interfere with polyphosphate activity

Scientists have identified a group of small molecules that interfere with the activity of a compound that initiates multiple steps in blood clotting, including those that lead to the obstruction of veins or arteries, a condition called thrombosis. Blocking the activity of this compound, polyphosphate, could treat thrombosis with fewer bleeding side effects than the drugs that are currently on the market.

7 Nov 2012

NAI receives U.S. patent allowance for sustained release beta-alanine products

Natural Alternatives International, Inc., a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance of its patent application directed to sustained release formulations of beta-alanine.

6 Nov 2012

Compound News and Research

USPTO grants patent for galactomannan-based carbohydrate galectin inhibitor compounds

Researchers characterize novel lysosomal PQ protein linked to cystinosis

Iridoid synthase can make powerful chemicals from catnip to vinblastine

Citicoline not superior to placebo in treating traumatic brain injury

Study: 2-PMPA improves cognition in mice with MS

Diffusion Pharmaceuticals completes trans sodium crocetinate Phase I trial on glioblastoma

CLR01 effectively inhibits synaptotoxicity in mice with Alzheimer's

D737 compound restores motor function and longevity in fruit flies with Alzheimer's

RXi announces pharmacokinetic results from RXI-109 Phase 1 study in healthy subjects

Viewpoints: Voters want Medicare protected in 'grand bargain;' Increases in taxes can't cover the 'fiscal cliff'; Kids' health needs more attention

Brevetoxin-2 stimulates nerve cell growth and plasticity in cultured mouse neurons

Combination of hormones may effectively treat obesity with few side effects

Taste receptor governs respiratory infection susceptibility

HCT 1026 may help stem debilitating effects of muscular dystrophy

UIC researchers develop transgenic Alzheimer's mouse with apoE4 gene

Study reveals increased risk of leukemia among Chernobyl cleanup workers

Washington University, SRI investigators launch Global Metabolomic Initiative

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Scientists identify group of small molecules that interfere with polyphosphate activity

NAI receives U.S. patent allowance for sustained release beta-alanine products

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News